https://www.facebook.com/share/p/1CU1QfHe5u/ Johns Hopkins’ New Mebendazole Patent and Its Significance for Cancer Therapeutics A recent public news article has highlighted a development that deserves serious attention within oncology and drug-repurposing research: Johns Hopkins scientists have patented a new crystalline form of mebendazole—referred to as polymorph C—designed to enhance its anti-cancer properties. Background: Why Mebendazole Matters Mebendazole is a benzimidazole-class anthelmintic with a well-characterised safety profile accumulated over ~40 years of clinical use. Beyond its antiparasitic activity, numerous preclinical studies have demonstrated: Microtubule inhibition in cancer cells Disruption of glucose metabolism in malignant tissues Interference with multiple signalling pathways (Hh, Wnt/β-catenin, Bcl-2) Selective cytotoxicity to tumour cells at concentrations tolerated by normal cells Despite these properties, clinical adoption has been limited largely because the original molecule is off-patent, making large-scale commercial trials financially unviable. What Johns Hopkins Has Patented The new patent centers on: Polymorph C — a redesigned crystalline form This form appears to demonstrate: Improved oral absorption Higher plasma concentrations Prolonged systemic exposure Greater potency in killing cancer cells in vitro compared with existing polymorphs This is scientifically notable, because mebendazole traditionally suffers from: Poor gastrointestinal absorption High inter-individual variability Low bioavailability unless taken with high-fat meals A more bioavailable crystalline form directly addresses these limitations. Synergy Through Transporter Inhibition The Johns Hopkins team also referenced co-administration with elacridar, a potent inhibitor of: P-glycoprotein (P-gp) Breast Cancer Resistance Protein (BCRP) These efflux pumps are responsible for removing chemotherapeutic agents from cancer cells.

I am not sure if this publication has been posted or not but I have just come across it through a video I had gotten screening access to. Here is a link to the website and attached is the publication. https://www.sovrintv.com

My cancer was initially diagnosed between 1 & 2 stages for which I supplemented. I am back trying to piece together an oncologist and location or system for care. I have traditionally inadequate health insurance and need help navigating what works for a throat tumor, mantle cell lymphoma diagnosis. I unsuccessfully tried to schedule tumor reduction surgery followed by carbon ion therapy. I welcome the sharing of experiences.

Hi all, This was something I only recently became aware of so though i should share it. Key Findings from Research :https://pmc.ncbi.nlm.nih.gov/articles/PMC3262853/ Animal Study Evidence: A 2011 study in mice found that pretreatment with fenbendazole (at doses equivalent to 8–12 mg/kg/day for 7 days) significantly worsened acetaminophen-induced liver damage. Specifically:Acetaminophen alone caused centrilobular hepatic necrosis and elevated liver enzymes (ALT/AST) within 12 hours.When combined with fenbendazole, the damage was more extensive, with greater necrosis, higher enzyme levels, and 63% mortality within 24 hours.Fenbendazole alone did not cause liver issues.The mechanism appears to involve prolonged depletion of glutathione (GSH), a key antioxidant that detoxifies acetaminophen's toxic metabolite (NAPQI). Fenbendazole delayed GSH recovery without altering acetaminophen's metabolism or major cytochrome P450 enzymes (except a minor suppression of CYP1A2).This interaction was investigated because fenbendazole is commonly used in lab rodents, and it highlights a potential drug-drug effect in hepatotoxicity models. Human Relevance: There are no published clinical trials or case reports confirming this interaction in humans. Fenbendazole is not FDA-approved for human use (it's a veterinary dewormer), so data is limited to off-label contexts like experimental cancer protocols. Both drugs are metabolized in the liver via the cytochrome P450 system, which could theoretically lead to similar risks, such as altered drug clearance or compounded stress on liver function. Sites promoting fenbendazole use (e.g., for alternative therapies) note this as a speculative concern and recommend monitoring liver enzymes (ALT/AST) if combining them, along with liver-supportive supplements like milk thistle.

Hey guys, I was hoping to hear how people's experience with radiation has been. My dad has stage 3 lung cancer, diagnosed in July 2025. He has had one round of chemotherapy (carboplatin) and immunotherapy (pembrolizumab) but unfortunately had a severe reaction with deranged liver function. He's been on prednisolone and mycophenolate since September to manage the liver issues, which have now thankfully normalised, he's on a weaning steroid dose now. He has been on a ketogenic diet with ivermectin since August and was on fenbendazole when his liver went off. We have stopped the fenben in case it was contributing. No more chemo for now because of the immunosuppression. He had a repeat CT scan this week which shows stable known lymph node and primary, with 2 new non-descript ground glass nodules inthe lung near his kn own primary. Unclear significance at this stage. They are now suggesting a few weeks of radiation to the lymph nodes in his chest. We are cautious of the radiation given the extreme side effect of the other conventional treatments which have affected our ability to really give metabolic therapy a proper go. Does anyone have any thoughts or experience they could share? Thanks